We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Noninvasive Prenatal Test Assesses Risk for Aneuploidies

By LabMedica International staff writers
Posted on 28 Sep 2014
Print article
A noninvasive prenatal test (NIPT) employs next-generation sequencing to assess risk for multiple fetal chromosomal aneuploidies from a single blood sample.

Laboratory Corporation of America Holdings (LabCorp; Burlington, NC, USA), a pioneer in diagnostic testing, has announced the availability of the “informaSeq Prenatal Test”—an advanced, noninvasive, next-generation prenatal screening assay that can assess risk for multiple fetal chromosomal aneuploidies from a single maternal blood draw. In addition, there are testing options specifically for several common sex-related aneuploidies. The test is offered through Integrated Genetics, part of the LabCorp Specialty Testing Group of laboratories that offer advanced esoteric and genomic testing (LabCorp also conducts clinical trials testing through its LabCorp Clinical Trials division).

The American Congress of Obstetricians and Gynecologists (ACOG) and the Society of Maternal Fetal Medicine (SMFM) have recognized the tremendous potential of offering cell-free DNA (cfDNA) testing to patients at increased risk of aneuploidy. The informaSeq Prenatal Test is performed using Illumina sequencing technology to generate test data, offering high detection rates (sensitivity) and low false positive rates (specificity), even in samples with a lower fraction of fetal DNA fragments.

In addition to the informaSeq Prenatal Test, Integrated Genetics offers reproductive genetic screening and diagnostic options to support a physician’s pregnancy management protocols. To help physicians and patients understand the results of those tests and identify risk factors, Integrated Genetics employs a large network of Board-certified genetic counselors, helping physicians and patients make more informed decisions.

“The noninvasive informaSeq Prenatal Test provides clinicians with another option to aid in the diagnosis and care of their patients,” said Dr. Mark Brecher, LabCorp’s chief medical officer, “This test is the latest example of LabCorp's continued commitment to introduce diagnostic tools that deliver advanced clinical information, enhance physician decision making, and improve patient outcomes.” “As a global leader in reproductive and genetic health solutions, we are very pleased to support this NIPT offering by LabCorp,” said Tristan Orpin, senior vice president and general manager of Reproductive and Genetic Health for Illumina, “We are committed to making NIPT more broadly available and the launch of this product will help expand access.”

Related Links:

LabCorp


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more